← Browse by Condition
Medical Condition

pancreatic adenocarcinoma

Total Trials
14
Recruiting Now
14
Trial Phases
Phase 2, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for pancreatic adenocarcinoma?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for pancreatic adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic adenocarcinoma?
pancreatic adenocarcinoma research spans Phase 1 (6 trials), Phase 2 (5 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic adenocarcinoma clinical trial?
Eligibility criteria for pancreatic adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
6
Phase 2
5
Phase 3
2
Top Sponsors
Erasme University Hospital 1 trial
Anwaar Saeed 1 trial
Fudan University 1 trial
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 1 trial
University of Chicago 1 trial

Recruiting Clinical Trials

NCT05083247 Phase 2
Recruiting
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Enrollment
256 pts
Location
Belgium
Sponsor
Erasme University Hospital
View Trial →
NCT06896188 Phase 1
Recruiting
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Enrollment
12 pts
Location
United States
Sponsor
Anwaar Saeed
View Trial →
NCT06250972 Phase 3
Recruiting
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
Enrollment
210 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06892054 Phase 1
Recruiting
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Enrollment
15 pts
Location
France, Spain
Sponsor
Spanish Cooperative Group for ...
View Trial →
NCT04361708 Phase 1
Recruiting
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Enrollment
54 pts
Location
United States
Sponsor
University of Chicago
View Trial →
NCT06388967
Recruiting
Pancreatic Cancer Detection Consortium
Enrollment
2,000 pts
Location
United States, Japan...
Sponsor
City of Hope Medical Center
View Trial →
NCT05877599 Phase 1
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Enrollment
45 pts
Location
United States
Sponsor
AstraZeneca
View Trial →
NCT05624918 Phase 2
Recruiting
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Enrollment
38 pts
Location
United States
Sponsor
Ashish Manne
View Trial →
NCT05985655 Phase 1, Phase 2
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Enrollment
230 pts
Location
United States, Belgi...
Sponsor
Exscientia AI Ltd., a wholly o...
View Trial →
NCT07491445 Phase 3
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment
900 pts
Location
United States, Austr...
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT06789679 Phase 2
Recruiting
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Enrollment
128 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT05776342
Recruiting
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
Enrollment
4,050 pts
Location
France
Sponsor
GERCOR - Multidisciplinary Onc...
View Trial →
NCT05000294 Phase 1, Phase 2
Recruiting
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Enrollment
29 pts
Location
United States
Sponsor
University of Florida
View Trial →
NCT05059444
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Enrollment
2,020 pts
Location
United States, Franc...
Sponsor
Guardant Health, Inc.
View Trial →

Related Conditions

pancreatic cancer (2) non small cell lung cancer (2) breast cancer (2) ovarian cancer (2) pancreatic neoplasm (1) borderline resectable pancreatic adenocarcinoma (1) gastroesophageal junction adenocarcinoma (1) adenocarcinoma (1) pancreatic carcinoma (1) pancreatic ductal adenocarcinoma (1) pancreatic neoplasms (1) pancreatic cancer stage i (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology